Impact of TP53 mutations on survival outcomes in the CAR-T era of large B-cell lymphoma.

Purpose: mutations are among the strongest adverse prognostic factors in large B-cell lymphoma (LBCL) treated with chemoimmunotherapy. Whether this unfavorable prognostic impact persists in the era of chimeric antigen receptor (CAR) T-cell therapy remains controversial, largely due to the lack of non-CAR-T comparator cohorts. We aimed to explore whether the adverse prognostic impact of TP53 mutations differs according to treatment modality, particularly in patients receiving CAR-T therapy versus chemotherapy-based approaches. Patients and methods: mutation status and treatment modality. Treatment responses were assessed per Lugano 2014 criteria. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method and compared using log-rank tests. Results: mutation status. Conclusion: alterations.